The Japanese Ministry of Health, Labor and Welfare yesterday filed a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis AG over alleged exaggerated advertising of a popular blood-pressure drug, the company said.
The ministry lodged its complaint against Novartis Pharma KK following months of scandal after a university said the data in clinical studies might have been skewed to promote blood-pressure drug Diovan, which is also known as Valsartan.
“Today, a criminal complaint was filed by the health, labour and welfare ministry against us over doctor-led clinical research on Diovan for alleged exaggerated advertising banned under the pharmaceutical law,” a statement on the company’s Web site said. “We apologise deeply for causing tremendous worries and trouble to patients, their families, medical workers and the public. We take this incident extremely gravely and will continue to cooperate fully with the authorities.”
Japanese Minister of Health, Labor and Welfare Norihisa Tamura has characterized as “extremely regrettable” the incident in which an employee of the world’s No. 2 drug maker hid his affiliation during a medical study into the effects of the drug.
The resulting studies suggested the drug, which is licensed for use in more than 100 countries, had some additional preventative effect on strokes and angina.
The firm used data from the studies to market its drug, playing up its supposed additional benefits.
There is no suggestion that Diovan is ineffective in combating blood-pressure problems.
Under Japan’s pharmaceutical law, anyone found guilty of exaggerated advertising can be punished with up to two years in prison or a fine of as much as ¥2 million (US$19,400).
Novartis chief executive David Epstein has apologized for the concern the incident caused, but did not say that the company played any role in the allegations.
Meanwhile, prosecutors in New York said a Novartis unit paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood-transfusion drug it produces, according to an amended complaint filed on Wednesday in a civil case brought by state and federal prosecutors in New York.
East Hanover, New Jersey-based Novartis Pharmaceuticals Corp boosted its sales of the iron-reduction drug Exjade by giving referrals and rebates to pharmacy BioScrip, which recommended refills to its patients, but often ignored to warn them about the drug’s potentially fatal side effects, which include kidney failure and gastrointestinal hemorrhaging, according to the complaint filed in the federal court in Manhattan.
BioScrip, based in Elmsford, New York, agreed to pay US$15 million to settle charges that it caused pharmacies to submit tens of thousands of false claims to Medicare and Medicaid, New York Attorney General Eric Scheniderman said.
“This arrangement between Novartis and BioScrip was dangerous for patients and is against the law,” Scheniderman said in a statement. “Our lawsuit against Novartis and our agreement with BioScrip send a clear message: Drug companies cannot pay pharmacies to promote drugs directly to patients.”
In a statement, Novartis Pharmaceuticals disputed the allegations and said it would defend itself against the litigation.
As part of its settlement with the government, BioScrip said that, beginning in 2007, Novartis told the pharmacy its refills for Exjade patients were too low and that it would lose referrals if it did not raise its numbers, according to court documents.
The pharmacy, using employees in an Ohio call center, encouraged patients — some who had stopped using the drug — to refill their Exjade orders, according to the lawsuit.
The lawsuit seeks tens of millions of dollars in Medicare and Medicaid reimbursements.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to